Drug development

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Retrieved on: 
Monday, April 8, 2024
Max Planck Society, Attention, CDMO, Growth, MSA, Master service agreement, CGMP, Laboratory, Drug development, Administration, Pharmaceutical industry

Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system.

Key Points: 
  • Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system.
  • Ayana COO Yanir Aldouby, commented, "After an extensive search, we are pleased to have selected Scinai Bioservices as our CDMO for our future projects.
  • We were particularly attracted to the team's experience in bio-pharmaceutical drug development and manufacturing for clinical trials while meeting stringent international regulatory requirements.
  • As Scinai is also in the business of biological drug development, we believe they understand our needs as a small biopharma company.

Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland

Retrieved on: 
Friday, April 5, 2024
Diagnosis, Brain, Dementia, Growth, Doctor of Pharmacy, LMI, Deficit spending, Partnership, Patient, PET, Research, Radiopharmaceutical, Drug development, FDA, Physician, Medical imaging

BOSTON, April 5, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE's radiopharmaceutical manufacturing site located in Cleveland, Ohio. The first doses have been made available on April 4, 2024.

Key Points: 
  • BOSTON, April 5, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE's radiopharmaceutical manufacturing site located in Cleveland, Ohio.
  • "By adding Cleveland to our distribution network, Life Molecular Imaging is thrilled to provide additional availability of Neuraceq®, an important imaging tool for the detection of beta-amyloid plaques in the brain.
  • Brian Schumer, PharmD, SOFIE COO states, "We are excited to bring Neuraceq® availability to another SOFIE network site.
  • SOFIE is committed to the further expansion and availability of LMI's Neuraceq® PET diagnostic tracer throughout our national PET manufacturing and dispensing network."

Element Biosciences Announces Availability of AVITI24, the First Benchtop Sequencer Capable of Direct Cell Profiling

Retrieved on: 
Friday, April 5, 2024
MAPK, Today, Science, SAN, DSM-IV codes, Neoplasm, Research, RNA, DNA, Element, Cancer, Neuroscience, Doctor of Philosophy, Protein, AACR, Drug development, Phosphoprotein, Annual general meeting, Vaccine

SAN DIEGO, April 5, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, has begun taking orders for AVITI24™ the first instrument to combine state-of-the-art sequencing and cyto-profiling (mapping cell characteristics) into a single integrated biology platform, the company announced at the Annual Meeting of the American Association for Cancer Research.

Key Points: 
  • AVITI24 revolutionizes research by enabling simultaneous examination of DNA, RNA, proteins, phosphoproteins, and cell structure within single cells.
  • Powered by Element's new Teton™ chemistry, AVITI24 expands on AVITI's best-in-class sequencing capabilities to offer new multi-omics functionality, simplifying results in one multi-omic read-out in less than 24 hours.
  • This technology is particularly relevant for cancer researchers, facilitating in-depth exploration of the links between the molecular makeup of cancer cells and how they function within complex tumors.
  • "Today, we are redefining what a sequencer can do by streamlining multiple conventional stages of discovery into a single powerful platform," said Molly He, PhD, CEO and co-founder of Element Biosciences.

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

Retrieved on: 
Thursday, March 28, 2024
Novartis, Acute lymphoblastic leukemia, Head, LG, Translational research, Urology, Oncology, Drug discovery, Executive, LG Chem, Lung, Anschutz Medical Campus, Committee, SRL Diagnostics, University, Laboratory, Doctor of Philosophy, RWTH Aachen University, Senior, Radiopharmaceutical, European Medicines Agency, ARUP Laboratories, Therapy, Drug development, Pharmacology, Pharmaceutical industry

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Key Points: 
  • BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
  • “We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company.
  • Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee (“Committee”).
  • The Scientific Advisory Committee is comprised of several leading cancer experts, including:
    Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology
    University of Colorado Cancer Center, Aurora

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on: 
Monday, March 25, 2024
Survival, Verge, ALS, Caregiver, Social justice, Partnership, Patient, SAN, Tissue, News, Business development, Ferrer, POC, Neuron, B Corporation (certification), Clinical trial, Genomics, DSM-IV codes, Drug development, Safety, CONVERGE, Pharmaceutical industry

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points: 
  • VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
  • Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
  • Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
  • “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, March 25, 2024
Research, FASN, Fatty liver disease, Congress, Exercise, Progression-free survival, F2, Patient, SAN, Food and Drug Administration, F3, G&A, IPO, Obesity, IND, Acne, Bevacizumab, Glioblastoma, Fibrosis, Clinical trial, NASH, FDA, Drug development, Pharmaceutical industry

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31, 2023, and provided corporate updates.

Key Points: 
  • In January 2024, Sagimet sold 9,000,000 shares of its Series A common stock in an underwritten public offering and received $104.7 million in net proceeds.
  • In November 2023, Sagimet presented preclinical data evaluating denifanstat alone or in combination with semaglutide in mouse models of MASH at the 7th Obesity and NASH Drug Development Summit.
  • In October 2023, Sagimet’s license partner for China, Ascletis Bioscience Co. Ltd. (Ascletis), presented Phase 2 topline results at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.
  • In July 2023, Sagimet closed an upsized IPO of Series A common stock, at a public offering price of $16.00 per share.

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

Retrieved on: 
Monday, March 25, 2024
Transfer, Growth, Biotechnology, CFO, Research, NOL, Sale, Drug development, Workforce

LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses (NOLs). The NOL sales are administered through the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program. This non-dilutive funding further strengthens the Company’s balance sheet.

Key Points: 
  • LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses (NOLs).
  • The NOL sales are administered through the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program.
  • “This program offered by the NJEDA provides IMUNON with investor-friendly ways to finance its clinical development programs,” said Jeffrey W. Church, IMUNON’s executive vice president and CFO.
  • IMUNON is one of several biotechnology/technology companies to qualify in this competitive process to share in the funding this year.

PCOM, The Wistar Institute Announce Cancer Biology Graduate Program

Retrieved on: 
Wednesday, March 20, 2024
Wistar Institute, Drug discovery, Patient, PCOM, Research, News, Cancer, Doctor of Philosophy, Faculty, Student, Drug development, Biomedical sciences, School

Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer.

Key Points: 
  • Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer.
  • , Wistar President and CEO, director of its Ellen and Ronald Caplan Cancer Center and the Robert and Penny Fox Distinguished Professor.
  • The Cancer Biology Graduate Program—jointly administered by Wistar and PCOM—will train individuals for a successful academic or industrial career in cancer biology and drug development.
  • At the conclusion of their studies, successful candidates will be granted a Ph.D. in cancer biology from PCOM.

Intelligencia AI Ranks No. 90 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies  

Retrieved on: 
Wednesday, March 20, 2024
Intelligentsia, Patient, Growth, Drug development

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Inc. magazine recently revealed that Intelligencia AI , a provider of AI-powered decision-making solutions for the pharmaceutical industry, ranks No.

Key Points: 
  • NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Inc. magazine recently revealed that Intelligencia AI , a provider of AI-powered decision-making solutions for the pharmaceutical industry, ranks No.
  • 90 on the fourth annual Inc. 5000 Regionals: Northeast list , the most prestigious ranking of the fastest-growing Northeast private companies.
  • Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful companies within the Northeast economy’s most dynamic segment–its independent small businesses.
  • The companies on this list show a remarkable rate of growth across all industries in the Northeast region.

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

Retrieved on: 
Tuesday, March 19, 2024
Conditional sentence, History, GI, Therapy, Drug development, Inflammatory bowel disease, FDA, Autoimmunity, Pharmaceutical industry

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.

Key Points: 
  • WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.
  • Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics.
  • Of particular relevance to Morphic as we advance MORF-057, is Simon’s experience in the development and approvals for therapeutically effective and commercially successful autoimmune and inflammatory agents in the GI space,” commented Praveen Tipirneni, Chief Executive Officer of Morphic.
  • I am also excited about the prospects for Morphic research programs for small molecules against non-integrin immunology targets and am looking forward to working with the Morphic Team,” commented Dr. Cooper.